Skip to main content
. 2020 Aug 14;44(5):1949–1960. doi: 10.3892/or.2020.7735

Figure 2.

Figure 2.

Flow cytometry using anti-CD44 mAbs. (A) CHO/PA16-CD44v3-10 cells were treated with C44Mab-5 and 5-mG2a-f (1 µg/ml), followed by secondary antibodies. (B) CHO-K1 cells were treated with C44Mab-5 and 5-mG2a-f (1 µg/ml), followed by secondary antibodies. (C) SAS cells were treated with C44Mab-5 and 5-mG2a-f (1 µg/ml), followed by secondary antibodies. (D) HSC-2 cells were treated with C44Mab-5 and 5-mG2a-f (1 µg/ml), followed by secondary antibodies. The black line represents the negative control. mAbs, monoclonal antibodies.